)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
Oncopeptides
Oncopeptides (ONCO) investor relations material
Oncopeptides Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary19 Feb, 2026
Executive summary
Net sales more than doubled year-over-year to SEK 71.1 million in 2025, with Q4 sales up 88% to SEK 18.6 million, driven by strong Pepaxti demand, especially in Italy, and successful market access in Spain and Italy.
Over 600 patients treated with Pepaxti since EMA approval, supported by positive clinical data and inclusion in updated EHA/EMN guidelines.
Announced a SEK 200 million rights issue, mostly guaranteed, to fund commercialization and pipeline expansion, especially in glioblastoma.
Strategic review completed for German and R&D operations to sharpen focus and optimize the business model, with resource reallocation from preclinical to clinical research and cost reductions implemented.
Strategic focus on expanding Pepaxti commercialization in Europe and advancing pipeline assets, especially in glioblastoma, leveraging the PDC platform.
Financial highlights
Full-year net sales reached SEK 71.1 million, a 125% increase from 2024; Q4 net sales were SEK 18.6 million, up 88% year-over-year.
Gross profit for the year was SEK 68.7 million, with a gross margin of 97%.
Operating expenses decreased by 16% in Q4 and 7% for the full year, indicating cost control.
EBIT improved to SEK -224.7 million from SEK -283 million last year; full-year net loss was SEK -249.6 million, improved from SEK -284.6 million in 2024.
Cash at year-end was SEK 82 million, with liquidity to be strengthened by the rights issue.
Outlook and guidance
Targeting positive cash flow in 2027, revised from previous guidance of 2026 due to slower growth in key markets and external disruptions.
Proceeds from the rights issue will fund continued commercialization and clinical development, especially for glioblastoma.
Expecting to initiate a window of opportunity (phase 0) clinical study in glioblastoma in 2026.
Country-level profitability in Germany targeted for 2026.
How will Germany's strategy ensure 2026 profitability?
What's next after glioblastoma BBB study results?
How does Japan deal delay affect ex-EU strategy?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Oncopeptides earnings date
Q1 202613 May, 2026
Oncopeptides
Next Oncopeptides earnings date
Q1 202613 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Oncopeptides AB, a biotech company, focuses on the development of therapies for patients with cancer. The company's lead drug candidate is melflufen, which has received orphan drug designation from the European Commission, as well as from the FDA for the treatment of multiple myeloma. Its product pipeline also comprises peptide-drug conjugates that are in preclinical stage development for hematological malignancies and solid tumors. The company is based in Stockholm, Sweden
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage